Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$2.19B |
| 2 |
GE Vernova
GEV
|
+$1.16B |
| 3 |
Meta Platforms (Facebook)
META
|
+$501M |
| 4 |
Palantir
PLTR
|
+$451M |
| 5 |
DoorDash
DASH
|
+$411M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.22B |
| 2 |
Ascendis Pharma A/S
ASND
|
+$866M |
| 3 |
Applovin
APP
|
+$690M |
| 4 |
DAY
Dayforce
DAY
|
+$576M |
| 5 |
Workday
WDAY
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.5% |
| 2 | Healthcare | 20.49% |
| 3 | Industrials | 11.17% |
| 4 | Consumer Discretionary | 9.27% |
| 5 | Communication Services | 8.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Stoke Therapeutics
STOK
$1.82B
| $52.5M | 0.03% |
1,612,781
+161,848
| +11% | +$5.31M |
|
402
Entegris
ENTG
$19.7B
| $52.4M | 0.03% |
446,888
+8,172
| +2% | +$966K |
|
403
Equity Lifestyle Properties
ELS
$12.8B
| $51.9M | 0.02% |
831,809
+23,553
| +3% | +$1.53M |
|
404
Advanced Micro Devices
AMD
$851B
| $51.9M | 0.02% |
255,517
+2,965
| +1% | +$633K |
|
405
Hartford Financial Services
HIG
$38.5B
| $51.9M | 0.02% |
383,504
+20,197
| +6% | +$2.76M |
|
406
Silgan Holdings
SLGN
$4.91B
| $51.7M | 0.02% |
1,333,657
-200,269
| -13% | -$8.79M |
|
407
Jackson Financial
JXN
$8.32B
| $51.3M | 0.02% |
484,713
+116,436
| +32% | +$13M |
|
408
Kodiak Sciences
KOD
$2.59B
| $50.5M | 0.02% |
1,325,457
+325,457
| +33% | +$8.41M |
|
409
Valmont Industries
VMI
$9.44B
| $50.3M | 0.02% |
125,830
+30,359
| +32% | +$13.3M |
|
410
Walker & Dunlop
WD
$1.65B
| $50.2M | 0.02% |
1,131,767
-51,713
| -4% | -$2.92M |
|
411
Ardelyx
ARDX
$1.24B
| $50.1M | 0.02% |
8,371,234
-6,143,458
| -42% | -$40.6M |
|
412
Tango Therapeutics
TNGX
$4.34B
| $50.1M | 0.02% |
2,394,972
-249,265
| -9% | -$3.47M |
|
413
Cloudflare
NET
$93B
| $49.8M | 0.02% |
241,367
+206,032
| +583% | +$39.3M |
|
|
TTAN
414
ServiceTitan Inc
TTAN
$6.72B
| $49.7M | 0.02% |
783,560
+11,362
| +1% | +$877K |
|
|
CPRX
415
DELISTED
Catalyst Pharmaceutical
CPRX
| $49.5M | 0.02% |
1,998,875
+279,108
| +16% | +$6.65M |
|
416
Robinhood
HOOD
$85.2B
| $49.5M | 0.02% |
713,962
+632,864
| +780% | +$55.6M |
|
417
4D Molecular Therapeutics
FDMT
$526M
| $48.9M | 0.02% |
5,247,151
+611,276
| +13% | +$5.32M |
|
418
Paylocity
PCTY
$6.71B
| $48.9M | 0.02% |
452,153
+222,593
| +97% | +$27.3M |
|
419
Alnylam Pharmaceuticals
ALNY
$36.3B
| $48.7M | 0.02% |
147,089
+10,664
| +8% | +$3.63M |
|
420
BioMarin Pharmaceuticals
BMRN
$11.5B
| $48.4M | 0.02% |
857,010
+580,680
| +210% | +$33.9M |
|
421
Churchill Downs
CHDN
$6.03B
| $48.1M | 0.02% |
535,309
-88,273
| -14% | -$8.39M |
|
|
WAY
422
Waystar Holding Corp
WAY
$4.32B
| $48M | 0.02% |
1,991,050
+1,201,359
| +152% | +$31.9M |
|
423
Rush Enterprises Class A
RUSHA
$5.95B
| $47.9M | 0.02% |
724,410
+330,553
| +84% | +$21.8M |
|
424
Everest Group
EG
$15.2B
| $47.8M | 0.02% |
146,288
-110
| -0.1% | -$36.2K |
|
425
Enanta Pharmaceuticals
ENTA
$372M
| $47.7M | 0.02% |
3,784,055
+54,396
| +1% | +$729K |
|
Similar funds
Janus Henderson Group's Q1 2026 Portfolio in Review
As of Q1 2026, Janus Henderson Group held 2,488 positions worth $209B, down 6.2% from $223B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Janus Henderson Group's Q1 2026 filing shows 82 new, 739 increased, 627 reduced and 81 closed positions. Its largest new stake was Forgent Power Solutions: 7,769,612 shares worth $227M. The largest sale was Microsoft, an estimated $1.22B.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 35% a quarter earlier, followed by Healthcare and Industrials.
- Janus Henderson Group's largest Q1 2026 buy was Forgent Power Solutions: 7,769,612 shares worth $227M.
- Janus Henderson Group added most to AstraZeneca in Q1 2026, an estimated $2.19B increase.
- Janus Henderson Group's biggest Q1 2026 reduction was Microsoft, cutting an estimated $1.22B.
- Janus Henderson Group fully exited Ascendis Pharma A/S in Q1 2026, selling an estimated $866M.
- Janus Henderson Group's ten largest holdings make up 30% of its $209B portfolio in Q1 2026.
- Janus Henderson Group opened 82 new positions and closed 81 in Q1 2026.
- Janus Henderson Group's portfolio value fell 6.2% quarter-over-quarter to $209B.
Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.